© 2022 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
IBI-20089, a drug candidate for the treatment of cystoid macular oedema (CME), has completed patient enrollment for initial clinical testing, according to the drug's manufacturer, Icon Bioscience Inc (IBI).